Although danirixin showed a trend for improved respiratory and health status in patients with COPD ( 7 ), the absence of a clear efficacy benefit has been confirmed in a larger clinical trial ( 13 ).
← all excerpts
Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.
1
—
—